eISSN: 2345-2781  
Submitted: 20 Oct 2017

Accepted: 04 Feb 2018
First published online: 19 Feb 2018
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)

Abstract Page Views: 564
PDF Downloads: 426
Full Text Views: 0
J Renal Inj Prev. 2018;7(2):89-93.
doi: 10.15171/jrip.2018.21

Scopus id: 85044777214

Original

Endoscopic correction of vesicoureteral reflux in children 

Mohsen Mohammad Rahimi 1, Surena Nazarbaghi 2, Rohollah Valizadeh 3, Sanam Fakour 4 * , Meisam Haghmoradi 5

1 Kidney Transplant Fellow, Kidney Transplant Division, Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
2 Department of Neurology, Imam Khomeini Hospital, Urmia University of Medical Sciences, Urmia, Iran
3 Student Research Commitee,Urmia University of Medical Science, Urmia, Iran and PhD Student in Epidemiology, Student Research Committee, Iran University of Medical Science, Tehran, Iran
4 General Practitioner, Urmia University of Medical Sciences, Urmia, Iran
5 General Practitioner, Mashhad University of Medical Sciences, Mashhad, Iran
Corresponding author: Sanam Fakour Email: sanam.fakour2000@gmail.com

Abstract

Introduction: Dextranomer/hyaluronic (Dx/HA) acid is the only tissue-augmenting agent approved by the Food and Drug Administration (FDA) for the vesicoureteral reflux (VUR) treatment.

Objectives: We aimed to evaluate short-term outcomes of the Dx/HA in patients who had undergone subureteric injection.

Patients and Methods: In this study, 30 patients with VUR diagnosis who had indications for open surgery were enrolled in the study. Patients underwent subureteric Dx/HA injection. Additionally patients underwent a one-year follow up period, subsequently. Follow up included urine analysis, urine cultures and kidney and urinary tract ultrasonography study.

Results: Of a total 30 patients, 8 patients (27%) were male and 22 patients (73%) were female. The mean age of patients was 25.19 ± 0.70 months. Postoperative VUR resolution was observed in 28 patients (93.3%). Moreover, during one year follow up, urinary tract infection (UTI) was not reported in patients. However, recurrent VUR was detected in 8 patients (27%) during ultrasonography follow up. Analysis showed no significant difference of recurrence in VUR between males and females (P = 0.285) and VUR severity (P = 0.1). There was a significant relationship between recurrent UTI history before intervention and VUR recurrence after subureteric injection (P = 0.007).

Conclusion: Dx/HA acid subureteric injection provides acceptable resolution rate among VUR patients, but its biodegradability causes VUR recurrence during one-year follow up.

Please cite this paper as: Mohammad Rahimi M, Nazarbaghi S, Valizadeh R, Fakour S, Haghmoradi M. Endoscopic correction of vesicoureteral reflux in children. J Renal Inj Prev. 2018;7(2):89-93. DOI: 10.15171/jrip.2018.21.
First name
 
Last name
 
Email address
 
Comments
 
Security code